King-Friend subsidiary receives FDA approval; buyback remains stalled
Nanjing King-Friend Biochemical Pharmaceutical (SSE:603707) announced that its subsidiary, Jianjin Pharmaceutical, has received U.S. FDA approval for its Hydralazine Hydrochloride Injection (20 mg/mL single-dose vial). The approval, under ANDA number 217501, covers the treatment of severe essential hypertension when oral administration is not feasible or rapid blood pressure reduction is required. Nanjing King-Friend noted that seven other companies already market similar Hydralazine Hydrochloride Injection products in the U.S., including Adrastea Pharma LLC and Hikma Pharmaceuticals USA Inc. The company has invested approximately CNY 1,105.97 million in the product’s research and development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Nanjing King-Friend Biochemical Pharmaceutical publishes news
Free account required • Unsubscribe anytime